Introduction
The Underlying Premise of Specific Humoral Immunity
Since the first report (Gottlieb et al. 1981 ) of a new immune disorder characterized by marked defects in cellular defenses and later termed the Acquired Immunodef iciency Syndrome (AIDS) , epidemiologic studies of the disease and of its etiologic agent, the human immunodef iciency virus (HIV) (Barre-Sinoussi et al. 1983) , have indicated a relatively recent and rapid spread (Bayley, 1984; Perre et al. 1984; Biggar, 1986) . The patterns suggest that until a few decades ago the virus existed in only very limited areas of the globe, and in those areas perhaps only as a non-pathogenic ancestor of the present agent (Biggar et al. 1985 ). Yet as is commonly known, HIV infection in humans or immunization in animals elicits a specific humoral defense reaction by the immune system, manifested by the production of immunoglobulins strongly reactive with HIV proteins. The teleological question then arises:
how can the immune system, having never had exposure to HIV throughout its evolutionary history, be prepared to mount a high- (Eised, 1971; Inman, 1974 Inman, , 1978 Richards et al. 1975; Dighiero et al. 1983 Dighiero et al. , 1985 Srinivasappa et al. 1986; Brient and Nisonof, f , 1970 of the overall mechanisms involved in generating specific humoral immunity may have arisen out of evolutionary necessity with the sophistication of higher organisms, the "selection" of antibody specif icities per se does not occur over Darwinian time but within each individual organism over days or weeks. The underlying premise upon which the logic or specific humoral immunity is based may be said to be that there is enough receptor diversity in an organism's complement of B-cells to provide adequate recognition of and response to at least one antigen on any potential intruding non-self agent.
Cognoeffector Functions are Independent of Response Branch
Although the enormous recognitive spectrum of the specific humoral immune system that this implies has long been acknowledged in immunology, the field from its beginnings has connected to clinical medicine through an emphasis of the response aspects of immunity. From a physiologic or therapeutic viewpoint, the utility of the vast recognitive repertoire of immunoglobulins has been generally regarded as being predicated upon recognition's direct tie to response: i. e. the repertoire allows precise recognition of an antigen, which allows stable binding, which allows physical linkage of the antigen to the network of immune system machinery.
However, in recent years there have emerged examples of reactions that involve antibody functions not necessarily related to the response branch of immunity. These may be classified as all immunoglobulin functions involving solely combining site regions and include, for example, antigen-like (antibody paratopes) (Meuer et al. 1983 ) (anti-Ti antibodies) (Ringden et al. 1977) , mitogen-like (anti beta-2 microglobulin) (Ringden and Moller, 1975; Sege and Peterson, 1978) , hormone-like (anti-insulin antiidiotypic antibodies) (Kahn et al. 1974 ) (Long-Acting Thyroid Stimulator antibodies-LATS) (Manley et al. 1974; Manley et al. 1974; Mehdi and Nussey, 1975; Sato et al. 1987 ) (anti-epidermal growth factor monoclonal antibodies) (Schreiber et al. 1980) , enzyme-like, and enzyme inhibitor -like reactivities.
Within the general class of combining site functions, we will particularly recognize as a group all those antibody reactivities that are capable of effecting a change in function of the antigen molecules toward which they are directed.
These functions will be termed cognoef f ector functions in as much as the process of recognition by antibodies itself in these cases results in a direct functional change in the target molecule.
An example of this type of immunoglobulin reaction is the mediation of catecholamine-like effects at beta-adrenergic receptors (Limdenmann, 1979) by what have been termed "homobodies" or "i nternal images of antigen" (Nisonof f and Lamoyi, 1981; Lerner, 1982) . These homobodies are anti-idiotypic antibodies which assume the biochemical properties of the original ligand molecule (or in this case, the opposite property-agonistic, as opposed to the antagonistic nature of the alprenolol immunogen) presumably by topochemical mimicry of the appropriate interacting surface. The intent of this communication is to review and relate data concerning a distinct type of cognoef f ector reactionenzymeinhibiting reaction, considering them in the light of recent advances and with particular attention to reverse transcriptases and HIV, and to discuss novel approaches they implicate for the utilization of the enormous recognitive capabilities of the immune system.
Reverse Transcriptase Inhibitory Serology
Multispecific Antibodies, Specific Sera
Antibodies
have been shown to react with a large number of molecular types and sizes, from viral glycoproteins to polysaccharides to small molecular weight haptens to short peptides (Atassi and Habeeb, 1977; Geysen, 1985) . Under the proper immunization conditions, all classes of substances tested, both naturally occurring and synthetic, have been shown to be potentially immunogenic; and in the case of protein antigens, immunoglobulins have been shown to be capable of reacting with every surfaceaccessible portion of the molecules (Armstrong et al. 1964; Schmitx et al. 1983; Geysen, 1985) . In addition to the breadth of its diversity, however, the humoral immune response possesses the capacity for a high specificity of binding to the eliciting antigen, discriminating it from other antigens of nearly identical structure.
For instance, it is a wellknown principle that single amino acid substitutions in protein antigens can yield large differences in serum affinity. Despite the presumable multispecif is nature of each individual immunoglobulin molecule (Brient and Nisonof, f , 1970; Eisen, 1971; Inman 1974; Richards et al. 1975; Inman, 1978; Dighiero et al. 1983; Dighiero et al. 1985; Srinivasappa et al. 1986 ), the serum immune response on the whole achieves a high degree of binding toward only one antigen in large measure because of its polyclonality : that is, because it is constituted by an admixture of antibodies directed against many different determinants on the target antigen. The result of this polyclonal production of multispecif is immunoglobulins is an elicited serum antibody with an exceedingly large total number of different reactivities, but with a high binding capacity (amount of antibody bound per unit antigen) to only one target antigen (Eisen, 1971; Inman, 1974; Richards et al. 1975; Inman, 1978) .
This property of serum antibody specificity has been utilized in the study of species relatedness through identification of cross-reactive antigens, and it was employed extensively for this purpose in the 1960's and 1970's in the study of RNA tumor viruses (Huebner et al. 1964; Berman and Sarma, 1965; Bauer and Janda, 1967; Gregoriades and Old, 1969; Maldonada and Bose, 1971; Oroszlan et al. 1971; Parks and Scolnick , 1972; Scolnick et al. 1972; Parks et al. 1973; Brugge et al. 1987; Temin and Mitsutani, 1970) . Antigen-antibody binding assays, such as immunodif f usion (Bauer and Janda, 1967; Gregoriades and Old, 1969; Maldona and Bose, 1971; Oroszlan et al. 1971; Parks and Scolnick, 1972) , complement-fixation (Huebner et al. 1964; Berman and Sarma, 1965; Parks and Scolnick, 1972) and later radioimmunoprecipitation (Scolnick et al. 1972; Parks et al. 1973; Brugge et al. 1987; Temin and Mitsutani, 1970) , were used extensively in cross-reaction studies among and within subgroups of RNA viruses for determination of relatedness in terms of group-and type-specif f is antigens.
Reverse Transcriptase Antigenicity and Inhibition
The discovery of an RNA-directed DNA polymerise (reverse transcriptase or RT) in these RNA viruses in 1970 (Baltimore, 1970; Gerwin and Todaro, 1970) , allowed for the analyses of the antigenicity and interspecies cross-reactivity of this enzyme.
It was soon discovered not only that reverse transcriptases exhibited strong antigenicity as measured by binding assays to sera raised against the different viruses, but also that some sera were capable of inhibiting the activity of the enzymes in an endogenous polymerase assay (Spiegelman et al. 1970) . Upon the refinement of reverse transcriptase assays (Scolnik et al. 1970; Aaronson et al. 1971; Goodman and Spiegelman, 1971 ), further studies demonstrated the purified serum inhibitory factors to be IgG immunoglobulins (Jacquemin et al. 1978) subsequently to be localized to F (ab') 2 fragments (Sherr et al. 1975; Okamoto et a1 1983; Laurence et al. 1987) , and that the purified serum IgG's were often inhibitory across several species of enzyme.
For example, rabbit antibodies raised against endogenous porcine virus were able to inhibit function of RT's from murine leukemia virus, simian sarcoma-associated virus, and gibbon ape leukemia virus, as well as that of the homologous (eliciting) enzyme (Parks et al. 1972) . Conversely, a given reverse transcriptase was capable of being inhibited by antibodies raised to each of several heterologous (cross-reacting) enzymes (Parks et al. 1972; Scolnick et al. 1972; Goldberg et al. 1974) . This RT inhibition by heterologous antibodies was used as an additional criterion for determination of interspecies cross-reactivity and, consequently, of immunologic relatedess (Parks et al. 1972; Jacquemin et al. 1978; Robert-Guroff and Gallo, 1979) . Correlations were demonstrated between the presence of RT inhibitory capacity in serum antibodies and the presence of enzyme-binding as measured in the standard immunological assays (Parks et al. 1972; Krakower et al. 1977) .
Enzyme Inhibition and Binding are Related but Distinct
Despite the correlations between binding and inhibition of enzymes and despite the utility of RT-cross-inhibition as a phylogenetic marker, binding and inhibition are distinct, albeit related, serologic phenomena.
In some instances serum antibodies inhibit retroviral polymerase activity in the presence of reduced binding (Jacquemin et al. 1978; Dauer and Temin 1980; Okamoto et al. 1983; Hattori et al. 1985; Inoue et al. 1989; Hattori et al. 1985) . IgG's in normal rabbit, rat, dog, and human sera have been shown to exhibit strong, specific inhibition of several species of RT-associated DNA polymerises with no polymerase binding detectable by radioimmunoprecipitation (Inoue et al. 1989 ). Since the amounts of IgG capable of 80-90% inhibition of the polymerase produce no stable complex formation, these phenomena have been explained by the presence of low-affinity antibodies and increased sensitivity of the polymerase assay for these antibodies over binding assays. Complete cross-inhibition by anti -murine leukemia virus RT antibody across several species of enzyme has been reported to occur in the presence of only partial radioimmunoassay binding, as compared to that of the homologous enzyme (Jacquemin et al. 1978) . Similar results have been obtained with purified IgG in a double-antibody immunoprecipitation assay (Okamoto et al. 1983) . Two cases of two HTLV-I-seropositive healthy carriers (out of 71) were recently described whose purified serum immunoglobulins were found to cross-inhibit HIV reverse transcriptase activity while failing to bind in anti-HIV immunoblotting and immunosorbent assays (Hattori et al. 1985) ( Fig. 1 ). It has been proposed that HIV, while not a transforming virion, may share a close phylogenetic relationship with HTLV-I, although absence of cross-reactivity between HTLV-I and HIV in binding assays has been previously demonstrated (Sarngadharan et al. 1985; Veronese et al. 1986) .
In this regard, the further characterization of a cross-reaction as either crossinhibiting, cross-binding, or both (or neither is a necessary one. What is intended in the term "cross-binding" is an interaction sufficient for detection by a binding assay, such as radioimmunopre- This is what has generally been referred to as "stable" binding by immunologists and is fundamentally distinguishable from an interaction involving the functional inhibition of an enzyme, which may not always require a highaffinity serum antibody interaction, as indicated by the examples above.
Stable binding is neither always sufficient nor always necessary for enzyme inhibition.
Anti-avian myeloblastosis virus sera capable of precipitating the homologous reverse transcriptase displayed no inhibition of enzyme function (Temin and Mitsutani, 1980) . Monoclonal antibodies strongly reactive with HIV pol gene products p51 and p66 and also ca- pable of absorption with the RT enzyme have been shown to lack RT-inhibitory capacity (Colman et al. 1987) . Thus, inhibition of retroviral enzymes does not correlate indiscriminately with binding ( Fig. 2) , but is selective for binding at one or more sites on the enzymes, most likely the active sites.
Low-Affinity
Inhibitory Sera: Detection in Cross -Reactions Direct inhibition of enzyme activity is not a phenomenon restricted to reverse transcriptases.
Influenza virus neuraminidase inhibition by monoclonal antibodies has been well established (Plant et al. 197) . The inhibitory capacity of immunoglobulins has been commonly employed in bacteriological studies for the detection of antistreptolysins, antistreptokinins, and antistapholoysins.
IgA's purified from normal human sera have been found to inhibit specifically the IgA protease of N. meningitides, and human secretory IgA's inhibited S. sanguinis and N. gonorrhoeae proteases (Robert -Guroff and Gallo, 1977; Gilbert et al. 1983) . Among examples from human enzymes, rat antiserum raised to human polymerase alpha has been shown to be capable of inhibiting the homologous enzyme, while binding to (but not inhibiting) human polymerase gamma (Robert-Guroff et al. 1977; Sanchez -pescador et al. 1985) .
While the occurence of serum antibodies inhibitory to enzymes in general is relatively common, the detection of inhibiting antibodies of a low affinity, such as those mentioned above, is a rare event.
Within the population of inhibitory antibodies elicited in an immunized or inf ected individual, antibodies with lowaffinity for the homologous enzyme (the eliciting antigen) generally are present in low titre and are thereby not readily detectable by an enzyme inhibition assay. Anitibodies whose production is to be stimulated are selected by the immune system on the basis of their affinity with the antigen, of course, not on the basis of their enzyme inhibitory capacity.
Although a set of B-cell clones with the potential of producing low-affinity, inhibiting antibody against the enzyme immunogen theoretically exists in an individual, this set is not preferentially stimulated in an immune response.
In serological studies, it is generally only in the context of cross-reaction analyses that the possibility of detecting such low-affinity inhibitory antibodies presents itself. For example, in the crossreaction of an inhibitory antibody with an enzyme from a virus, heterologous but related to the eliciting virus, the degree of structural similarity between the two enzymes in some instances may suffice for cross-inhibition, but not for crossbinding.
The pol gene products of HIV and HTLV-I have been shown to possess 28-42% sequence identity . It is likely that the structurally conserved regions include parts of the functionally active site, this if any interactions between anti-HTLV-I RT antibodies and HIV RT were to occur, it would not be expected that they would occur disproportionately at the polymerase active site. In these cases, while the cross-reacting antibodies are able to interfere directly with the function of the enzyme through binding, deficiencies in either affinity, extensiveness of binding to different determinants, or both result in the lack of a stable interaction, detectable in standard binding assays.
Inhibitory Antibody Binding
Antibody-Antigen Interactions: Implications of Non-Covalent Stereorecognition Enzyme-inhibiting antibody reactions in general and those involving pathogenassociated enzymes in particular are pharmacologically interesting, in so far as they are like all antibody-antigen interactions, based on selective stereorecognition.
The classical picture of lockand key three dimensional structural complementarity of antibody and homologous determinant has been validated by x-ray crystallographic data (Karush, 1976; Amit et al. 1986 ). Protruding areas on either of the antibody or antigen combining site surfaces match depressions on corresponding regions of the opposing surface, resulting in the "tight fit" necessary for formation of short-range bonds. One distinguishing characteristic of antibodyantigen reactions, however, has been thought to be the extent and complexity of the binding involved. Serum immunoglobulin reactions occur with overall standard free energy changes on the order of-6 to-13 kcal/mol, corresponding to affinity equilibrium constants in the range K=105-1010-1M
This degree of binding leads to the formation of stable antigen-antibody complexes in serum and allows for the carrying out of various immunoglobulin "effector" functions, such as virus neutralization, particle opsonization, complement lysis, and antibody-dependent cell cytotoxicity. The effectiveness with which immunoglobulins perform these binding-dependent operations is of course related to their affinity to the target antigen, which is why highaffinity antibody production is pref erentially stimulated.
However, the existence of inhibitory antibodies, and cognef f ector functions on the whole, invites a point of view from outside the context of mmunological of f ector functions.
First, while the total energies of antibody-antigen complexes result in stable "irreversible" binding, they are composed exclusively of reversible non-covalent interactions : electrostatic and hydrogen bonding, hydrophobic effects, and van der waals forces. In this sense the difference between the classical antibody-antigen interactions anisms secondary to binding immediately adjacent to the active site or 2) directly at a "regulatory site" distant from the active site, at which interaction with antibody results in a conformational alteration of the enzyme. This latter type of allosteric mechanism has been proposed for the antibody-mediated inhibition of neuraminidase (Plaut et al. 1979 ). Theories of inhibitory mechanisms involving multivalence, are not supported by these data. These observations taken as a whole suggest that inhibitory interactions may be viewed from a theoretical standpoint not only as the binding of immunoglobulin molecules to protein antigens, but as the inhibition by peptides of enzymes.
Protein Binding Site Versatility
That these enzymes are inhibited by direct anibody binding to the active site is consistent with previous observations made about affinities of binding sites on proteins.
Glazer (Glazer, 1970; Guilleminn, 1977) observed that active sites on various enzymes displayed much greater affinity for a variety of reactive dyes than did other parts of the proteins. Further, these reactive ligands, which bound preferentially to the binding sites, bore no obvious structural relationships with the natural enzyme ligands.
From these results, Glazer proposed that the design of a receptor for binding to a distinct class of substances does not limit its binding to that particular family. Enzyme binding site versatility has also been demonstrated by the capacity of natural substrates to bind to active sites in different modes-e. g. in productive and non-productive binding orientations.
In addition, some cellular receptors have been shown to demonstrate this type of muitispecif is binding toward seemingly structurally unrelated ligands: e. g. alkaloids as well as endorphins have been shown to bind opioid receptors functionally (Ahmed et al. 1984) , as has in-terleukin-2 (Padlan et al. 1973; Morley et al. 1987) , while the bacterial product muramyl depeptide has been shown to bind serotonin receptors.
These types of findings are also in agreement with the existence of low-affinity inhibitory antibodies.
Since increased reactivity appears to be an intrinsic property of active sites themselves, a property arising from structural features such as their characteristic concavity that provide a favorable chemical environment for the formation of multiple binding contacts, serum antibodies would be more likely to interact with the active sites on a heterologous enzyme than with other sites on the protein.
It is interesting to note that antibody combining sites, which exhibit multispecif icity themselves, also demonstrate concave structures Karush, 1976; Kabat et al. 1983; Bjokman et al. 1987) . Recently, crystallographic analysis of the HLA-A2 major histocompatability receptor, known to be a relatively non-specific, or multispecif ic, peptide receptor, has revealed the presence of a wedge-like binding site (Kohler and Milstein, 1975) . Disproportionate recognition of active sites by cross-reactive antibodies in relation to other sites on enzymes may be due, not only to the structural conservation of the functional site from species to species, but also due to the inherent hyperreactivity of enzyme binding sites in general. Expressed in another way, enzyme cross-inhibition by antibodies may occur not only as a type of shared (or Type 2) crossreactivity involving the expression of common epitopes on the two heterologous enzymes, but also as a manifestation of true (or Type 1) cross-reactivity of individual antibody molocules for similar but unidentical determinants determinants on the two molecules.
This effect also provides an explanation for the enzyme-inhibitory capacity, sometimes detected in normal sera. Fig. 3 depicts the scenario suggested. Fig. 3 . Enzyme binding site hyperreactivity model. Diagrammatic representation of four possible types of reactions between 2 different antibody combining regions and their eliciting (A) or cross-reactive (B) enzymes.
R and R'=regulatory or active sites. In b), the cross-reactive antibody's preferential interaction at the natural binding sites is a function of both the structural conservation of the sites and also of the inherent versatility of binding at a clift, which allows greater possibilities for complementarity than do other regions of the enzyme molecule.
Perspectives
Monoclonal
RT-Inhibitory Antibodies
The introduction of monoclonal anti-body techniques in 1975 and subsequent development and refinement has greatly facilitated the study of antibody antigen reactions, as well as that of the antibodies and antigens themselves and of the cells that produce and express them. The enormous utility of the method derives from its ability to select one particular reactivity from a pool of reactivities that may span all possible molecular structures within a given size distribution (i. e. up to the limiting area of the antibody-antigen contact surface).
Monoclonal antibodies have been prepared that possess inhibitory capacity against Rous sarcoma virus RT (Poljak et al. 1973) . The availability of large amounts of pure RT-inhibitory monoclonal antibodies potentiates the analysis of inhibiting interactions, which may be pharmacologically important because of the nature of inhibitory antibodies as specific for a particular type of polymerase.
Many inhibitors of reverse transcriptases, such as 3'-azido-3'deoxythymidine (AZT) and trisodium phosphonof ormate (Foscarnet), function by competition as analogues of natural substrate molecules: AZT with nucleotide triphosphates (Helgstrand et al. 1978) , and Foscarnet with pyrophosphate (Fischl et al. 1987) . Competition and subsequent inhibition in these cases is not exclusive to the RT enzymes, but extends to other nucleotide polymerases such as host DNA polymerase.
The clinical promise of AZT (Richman et al. 1987) has been diminished by its cytotoxicity (Chatter jee et al. 1987) . The antibody inhibitors of RT, which generally cross-react only within families of retroviruses (such as within mammalian Type C viruses) and which do not inhibit DNA polymerases, would seem to present an opportunity at selective attack upon the retroviral life-cycle. Because they are antibodies, these molecules inhibit by recognition of stereospecif is structural conformations particular to each type or family of virus rather than by simulating a substrate binding mode. While a given antibody may act at the RNA binding site of an RT, for instance, its binding most likely will not involve the same set of subinteractions occurring with nucleic acid binding at the same site.
There are at least two noteworthy conditions particular to the production of such inhibitory monoclonals against reverse transcriptases : 1) availability of pure RT for use as immunogen. The amount of reverse transcriptase present in retroviruses relative to other proteins is small (e. g. two molecules RT per HIV virus) and, at least in the case of HIV, the enzyme is thought to reside within the core protein.
In retroviral immunization experiments, unless the enzyme is separated from other viral proteins and inoculated in a relatively pure form, its immunogenicity is low. In infected animals and humans-AIDS patients, for example this immunogenicity increases most likely because large numbers of virions are produced and some are lysed in the serum, releasing the free enzyme (Sherr et al. 1975; Groopman et al. 1986 ) selection (or screening) of immunoglobulin-producing hybridoma cells by the functional assay rather than by immunoblotting or immunosorbent methods, since only a percentage of antibodies directed against enzymes are inhibitory at the appropriate concentrations.
In the case of AIDS-related disorders, while approximately 95% of seropositive individuals have been found to be anti-RT antibody positive the inhibitory capacity per unit immunoglobulin in these individuals varies over several orders of magnitude (Richman et al. 1987; Lee and Atassi, 1976) . As mentioned previously, monoclonal antibodies have been successfully prepared against reverse transcriptases. Since these preparations were not aimed directly at the isolation of anti-RT inhibiting clones screening was done on the DIVERSITY 21.9 basis of binding assays and immunizations performed with complete viral protein complements.
Consequently, some of these monoclonal antibodies are RT-inhibiting and some are non-inhibiting.
PharamacologicPossibilities
for RT-Inhibitory MoAb's In addition to the direct in vitro biotechnical uses of enzyme inhibitory monoclonal antibodies, these molecules would seem to present possibilities for in vivo therapeutic applications.
Where obstacles of delivery to and uptake by target cells overcome by such systems as virus-simulating liposomes, cleavage of HIV reverse -transcriptase inhibitory monoclonal antibodies to the smallest functionally active fragment (e. g. Fab) and incorporation of this product _ into the drug-delivery system would stand as a direct possibility (Fig. 4) .
The small number of interactions in the inhibiting systems also suggests the possibility of designing oligopeptide inhibitors of reverse transcriptase enzymes Fig. 4 . Hypothetical targeted liposome as a delivery system for RT-inhibitory antibody-derived fragments.
Immunologically intact reconstruction of antigens by incorporation into synthetic lipid bilayers has been achieved for various systems (see ref. Eriksson and Mattiasson, 1984 for review). In this model , incorporation of the HIV envelope glycoprotein into a lipid membrane results in simulation of the natural viral surface and endows the liposome with the capacity to assume both the virion's physiologically relevant immunogenicity and its routes of spread up to and including penetration of susceptible cells. from structural information generated from the monoclonal antibodies. The " surface simulation" technique, first proposed in 1976 (Twining and Atassi, 1978) , utilizes the capability of short peptides to "mimic" discontinuous binding sites. That is, binding sites formed from juxtaposed bends of separate stretches of a peptide chain, such as those observed at immunoglobulin combining regions, can be simulated by peptides containing the same residues as those of the binding site, ordered and distanced in such a way that they occupy the same relative spacial positions as those in the native molecule. This approach has been applied successfully to antibodies (Kazim and Atassi, 1980; Atassi, 1985) as well as antigens (Twining and Atassi, 1978) and enzyme binding sites (Lando et al. 1982) . For example, a peptide was designed from information about the known structure of the myeloma protein MCPC603 combining region.
The synthetic decapeptide, corresponding to the structure of a combining region subsite consisting of amino acid residues residing on several distinct regions of the polypeptide chain, demonstrated sensitive binding to phosphorylcholine, the natural ligand of the subsite. It is possible that the binding properties of the few critical residues in combining regions of inhibitory antibodies could be simulated in a similar manner by a short peptide of the proper sequence.
Because of the complex folding arrangements of peptide chains forming antibody combining sites (Karush, 1976; Kabat et al. 1983; Amit et al. 1986) , it is unlikely that por tions of antibody combining region subsites conferring inhibitory function are localized to a linear portion of one hypervariable loop, a condition which would otherwise render inhibitory peptide analysis and synthesis a relatively straightforward process. Weakly interacting inhibitory antibodies, however, suggest this possibility cannot in principle be ex- blobulins even though they are physiologically geared to react with quite different classes of substances. These protein binding site multispecif icity phenomena suggest a perspective which, in dissociating the importance of the individual subinteractions from that of the nature of the whole ligand and receptor molecules, reduces the roles of ligand and receptor mainly to those of support structures designed for the purpose of maintaining the few critical functional groups reacting at the interface in the proper complementary stereoconf iguration. That the treatment of non-covalent macromolecular interactions is in fact effectively reducible to that of the local interactions between topochemical surfaces is substantiated by a number of studies, including ones demonstrating 1) antibodies adsorb to cyanogen -bromide cleavage fragments of their homologous antigens (Wrenn and Haber, 1979) , antibodies can be induced against any surface-accessible portion of protein by immunization with a short, free peptide (not carrier-bound molecule) corresponding to the target antigenic segment (Geysers, 1985) , binding properties of both antibody binding sites and protein antigens can be "surface simulated" by peptides mimicking the appropriate 3dimensional surface conformations (Twining and Atassi, 1978; Kazim and Atassi, 1980; Atassi, 1985) . A thermodynamic interpretation of these results is that the overall free-energy change involved in the reaction of either a whole protein or one of its constituent peptides with a surface complementary molecule (such as antigen or antibody) is not so greatly affected by the entropy disparities created by replacing the whole protein with the short peptide, or vice versa, as to disrupt the overall interaction, provided the same surface interactions are allowed in either case. At least in as far as antibody-antigen interactions are con-cerned, and with reasonable extrapolation to other non-covalent macromoleclar interactions as well, intrinsic affinity of binding appears to be far more dependent upon the chemical and positional complementarity of the ligand surface with that of the receptor and the resulting capacity for establishment of short-range bonds than upon the overall structure of the ligand and the associated entropy considerations.
Further, if the same forces, atoms, and functional groups that mediate antibody binding can also result in the binding of a single amino acid, in the specific inhibition of a reverse transcriptase at an active site, or in the functional mimicking of a peptide hormone (Kahn et al. 1974; Manley et al. 1974; Manley et al. 1974; Mehdi and Nussey, 1975; Schreiber et al. 1980; Sato et al. 1987) or of a neurotransmitter at its receptor; then there is cause to believe that the same physical entities, cast in receptor, then there is cause to believe that the same physical entities, cast in the appropriate three-dimensional arrangement, could potentially react with positive offector sites on allosteric enzymes or with functionally important sites on other surface or intracellular receptors, in either agonistic or antagonistic modes. This extension of Glazer's hypothesis would imply the general applicability of cognoeffector antibody function to ligand-receptor systems.
Given the magnitude of the repertoire of immunoglobulins, the model would predict that at least some antibodies directed against the binding site of potentially any receptor molecule would present such topochemical surfaces as to mimic the effects of the natural ligand.
It has been demonstrated that antibody molecules are relatively rigid structures that undergo no detectable conformational change upon binding to antigen with the possible exception of rotation of side chains (Karush, 1976; Amit et al. 1986 ). The ability of this relatively rigid structure to confer function at a receptor suggests that at least in some cases a great deal of steric freedom is not a necessary condition for the action of of f ector organic molecules at their cellular receptors, post-binding physicochemical events being restricted to the receptor side of the interaction.
The antibody combining site inducing betaadrenergic effects, for instance, would not accomodate the same degrees of conf ormational freedom as the natural transmitter; and since the immunoglobulin is at most only a topochemical image of a beta-agonist, the only requisite for function at the receptor indeed appears to be the establishment of a sufficient, though not necessarily singularly predeterminate, spacial and chemical surface complementarity on a ligand-receptor level, the biological properties of an-OH group, not with standing the local chemical environment, may generally prove to be predominantly dependent upon its ability to assume the correct orientation in three-di mensional space relative to other interacting functions on both ligand and receptor, rather than upon the class of organic molecule upon which it resides.
Were this the case, given the stereorecognitive potential of immunoglobulin combining sites, the humoral immune system could be producing drugs-or drug models-in an elaborate form. That is, one could envision antibodies selected for particular cognoef f ector functions at specific receptors as at least providing "topochemical maps" as blueprints or guides for drug selection or synthesis. Given a topochemical map associated with a particular ligand effect at a receptor, molecules conforming or relating to the surface map could be selected or designed according to other properties, such as molecular weight or lipid solubility.
Reviewing the beta-agonist case as an example, this reductionist theory suggests that if the structure of a beta agonist were unknown, by analyzing the combining site interactions involved in binding of one or more beta-agonist-like monoclonal antibody combining sites to the adrenergic receptors and associated structures, one could construct surface maps of the ligand side of the agonistic interaction, and then proceed to find or design molecules with desired properties that also fulfilled or at least approximated these surface requirements. That the overall structures of the drug molecules resulting from this process need not a priori resemble those of known beta agonists is the clear implication of this reasoning.
Note further that one would be free to choose model antibodies of different affinities:
for instance, through clever selection of immunization conditions one could pear down the functional surface map by eliciting a low-affinity antibody to the target receptor, which need not of course be one and the same with the immunogen.
To employ enzyme inhibition as an example, the reverse transcriptase cross-inhibitory data suggest the following procedural combination: 1) immunization by an enzyme heterologous to, but related with, the target enzyme and 2) functional screening for inhibitory capacity against the target enzyme itself. This procedure would theoretically limit the number of combining site-enzyme subinteractions not involved in inhibition. For example, immunizing with HTLV-I RT and screening with HIV-RT would increase the propa bility of yielding anti-HIV RT inhibition with the least amount of overall binding.
The number and types of non-covalent bonds, and therefore the overall strength of the intrinsic interaction, are important in the context of cognoef f ector function only in as far as the minimum number of bonds necessary for functional effect establishes a lower limit to this overall binding energy.
Thus the high-affinity LATS reaction at the thyroid stimulating hormone receptor, to cite one example, would be expected to have lowaffinity functional counterparts, and one such "reversible" counterpart interaction is indeed realized physiologically by TSH. In contrast to classical of f ector functions, the key element in the participation of antibodies in cognoef f ector functions is not the strength of the overall interaction, but the "stereochemical-intelligence" or topochemical correctness of the binding. This functional screening in selecting these immunoglobulins would appear to afford variability in affinity. This dimension of variability is especially notable in view of the recognized difficulty of inducing antibody production to receptor binding sites (Limdenmann, 1979; Eriksson and Mattiasson, 1984) and of the successful use of "receptor-like" substances such as antibody idiotopes as immunogens to break such tolerance.
Conclusion : Utilizing the Sophisticated Machinery
The specific humoral immune system has evolved as a vertebrate defense mechanism designed for surveillance and sequestration of all foreign invaders that defy the organism's gauntlet of nonspecific defense components.
In order to achieve a capacity for effective attack upon each of millions of distinct potential intruders, it has seen the directed development of a sophisticated machinery capable of binding, with high affinity, not merely prespecif ied molecular portions of individual foreign substances representing significant evolutionary selective history, but the universal myriad of biochemical structures.
While the capability to bind specific substances such as particular microbial proteins, in constituting a positive selective advantage, may have driven the early evolving humoral immune system toward more extensive binding capacities and more intricate cel- 
